medisourceasia.com

Industry News


Home

About 
medisourceasia

Magazine
Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info

Contact

 

Association Of Indian Medical Device Industry (AIMED) : International Regulatory Update

SAFETY OF REPROCESSED MEDICAL DEVICES MARKETED FOR SINGLE-USE - ADOPTION OF SCIENTIFIC OPINION

The European Commission's independent Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) has recently published its opinion on the safety of reprocessed medical devices marketed for single-use. They say; A single-use medical device (SUD) is a device intended to be used once only for a single patient. Examples of SUDs are single-use syringes and needles, catheters and breathing tubes.

The Directive (93/42/EEC) regulating the placing of medical devices on the EU-market distinguishes between devices that are intended for reuse and those intended for single-use only. However, the practice of reprocessing SUDs is not regulated at EU-level and legislation in Member States differs. A few countries allow the reprocessing of SUDs, others prohibit the practice and some have no specific legislation.

The Commission asked the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) to assess whether the reprocessing of SUDs may constitute a hazard for human health.

Although clinical data is limited, the SCENIHR opinion identifies several potential hazards of re-using SUDs that may lead to a risk for patients. The opinion concludes that certain design features make a SUD unsuitable for reprocessing. Major hazards can arise from inadequate cleaning, disinfection and/or sterilization, resulting in contamination and possibly causing toxic reactions or infections. Chemicals used for disinfection may also affect the performance of the device. Areas of particular concern are the potential contamination with agents that cause transmissible spongiform encephalopathies (TSEs) and the risk of using reprocessed SUDs in invasive medical procedures. Other hazards mentioned in the opinion include poor traceability of a reprocessed SUD and loss of documentation such as the instructions for use.

The Commission will now finalize the report on the issue of the reprocessing of medical devices in light of the SCENIHR opinion and will submit it to the European Parliament and the Council in accordance with Directive 93/42/EEC.

Courtsey : Forum Co-ordinator
Association Of Indian Medical Device Industry, ( AIMED ).
GL-3 , Ashoka Estate, 24 , Barakhamba Road, New Delhi – 110 001

J&J Sees Fast-Growing Device Market : Plans 80 Regulatory Submissions For New Devices

*Plans 80 regulatory submissions for new devices

Johnson & Johnson (JNJ.N) sees itself competing in a faster-growing segment of the medical device market and plans about 80 "significant" regulatory submissions for its largest unit in the next two years.

J&J outlined its plans for the medical device business -- its top product category with annual sales of about $25 billion -- as it tries to overcome a manufacturing crisis at its consumer unit that makes Tylenol and other products.

Many analysts gathered at company headquarters in New Brunswick, New Jersey, on Thursday also hoped for an update about J&J's series of recalls of Children's Tylenol and dozens of other over-the-counter medications.

Management declined to discuss the recalls, which the U.S. Food and Drug Administration are investigating.

The company handled the recalls "sloppily," said Andrew Busser, portfolio manager at Symphony Capital in New York.

"Their execution and communication has not been crisp, but I don't think this will be meaningful long term," he said.

BDR analyst Matt Duffy said he was looking for signs that J&J is keeping its edge in devices and diagnostics against the likes of Abbott Laboratories Inc (ABT.N).

"There are a lot of questions about devices and diagnostics," Duffy said. "The stent business has been unbelievably competitive with (Abbott's) Xience taking over the world."

J&J said it has received more than a dozen regulatory approvals in 2010. Additional submissions will be rolled out across its seven franchises, including its DePuy orthopedics unit, Cordis cardiovascular business and Ethicon, which makes surgical instruments.

The maker of Band-Aids and Motrin told analysts it expects sales of the types of medical devices that it sells to grow by an average of 6 percent per year between 2009 and 2014. That would outpace growth of the wider medical device industry, which it forecast at 5 percent annually. J&J did not provide a forecast for its own medical device sales.

Total sales were $61.9 billion in 2009.

Shares of J&J were down less than 1 percent to $59.71 in afternoon trading on the New York Stock Exchange.

http://www.reuters.com/article/idUSN0325435620100603?
type=marketsNews

Other News

Planning Commission Examining Proposal For Rs 350 Cr Dedicated Medical Devices Park In Gujarat
Gujarat FDCA To Set Up Dedicated Testing Lab For Medical Devices In Baroda
Trivitron Inks Pack With IIT Madras To Set Up Biomedical R&D Centre In IIT Campus

Archives

Advertisement

 

 


Back | Back To Top | Previous | Next